On April 2, 2014, Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) a Delaware corporation (the “Company”), issued a press release announcing the appointment of Pankaj Bhargava, M.D., as the Company’s chief medical officer commencing March 31, 2014. Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) shares after opening at $23.75 moved to $24.26 on last trade day and at the end of the day closed at $21.41. Company price to cash ratio as 8.16. Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) showed a negative weekly performance of -26.30%.
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) on 1 April saw a big move last session, as the company’s shares fell by nearly 17% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares advanced 1.26% in last trading session and ended the day on $11.25. MNTA return on equity ratio is recorded as -52.90% and its return on assets is -46.00%. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) yearly performance is -12.79%.
Relypsa, Inc. (NASDAQ:RLYP) announced the appointment of Sylvia R. Wheeler to the position of Vice President, Investor Relations and Corporate Affairs. Ms. Wheeler, a veteran bio-pharmaceutical executive, joins Relypsa with over 20 years of experience in investor relations and corporate communications. In her new role, Ms. Wheeler will be a member of the leadership team and will report to John Orwin, President and Chief Executive Officer of Relypsa. Relypsa Inc. (NASDAQ:RLYP) shares moved up 2.07% in last trading session and was closed at $27.17, while trading in range of $21.85 – $27.38. Relypsa Inc. (NASDAQ:RLYP) year to date (YTD) performance is 8.68%.
Foundation Medicine and Clovis Oncology Inc. (NASDAQ:CLVS) Expand Collaboration to Develop Novel Companion Diagnostic for Rucaparib in Ovarian Cancer. Clovis Oncology Inc. (NASDAQ:CLVS) weekly performance is -8.06%. On last trading day company shares ended up $64.66. Clovis Oncology Inc. (NASDAQ:CLVS) distance from 50-day simple moving average (SMA50) is -13.07%. Analysts mean target price for the company is $101.29.